Global Blood Therapeutics Finds $48M
South San Francisco-based biopharmaceuticals firm Global Blood Therapeutics said this week that it has raised $48M in a Series B funding. The funding came from Wellington Management Company LLP, RA
Capital, Deerfield Management, Sabby Capital, Perceptive Life Sciences, along with an un-named public investment fund. The company said the funding will go towards its lead drug candidate, which is aimed at treating sickle cell disease (SCD). Global Blood Therapeutics is led by Ted W. Love.
posted on Thursday, January 8, 2015
Related companies:
Global 1 Source Group
Related stories:
> Global Blood Therapeutics Finds $40.7M For Sickle Cell Treatments
> Iconic Therapeutics Finds $20M
> Intarcia Therapeutics Finds $50M
> Eidos Therapeutics Prices IPO, To Debut Today
> Intuity Medical Finds $40M
silicontap.com Home